SOUTH SAN FRANCISCO, Calif., April 10 /PRNewswire/ -- Napo Pharmaceuticals, Inc., (LSE: NAPL and NAPU) is pleased to announce the positive results of a successfully completed Phase 2 trial for CRO-ID ...
Jaguar Health’s (JAGX) Napo Pharmaceuticals announced that the late-breaker abstract Napo submitted to MASCC on additional significant results in adult breast cancer patients from the OnTarget study ...
As announced, initial proof-of-concept results from the ongoing investigator-initiated trial in Abu Dhabi show crofelemer reduced the required total parenteral nutrition in the first participating ...
SAN FRANCISCO, CA / ACCESSWIRE / August 7, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), a commercial stage pharmaceutical company focused on developing novel, sustainably ...
Napo Pharmaceuticals (Napo), a Jaguar Health (Jaguar) family company, announced that the European Patent Office has issued a new patent to Napo for methods of preventing, ameliorating and/or treating ...
"We're very pleased that Napo has been granted a meeting with the FDA to discuss Napo's development plans for crofelemer for MVID - a devastating pediatric disease characterized by severe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results